Axovant Sciences Sets Terms For $269M IPO
Biopharmaceutical company Axovant Sciences Ltd. set terms for its initial public offering on Monday, as it looks to raise as much as $268.5 million to help develop a dementia therapy it...To view the full article, register now.
Already a subscriber? Click here to view full article